In view of this, more patients should be included and thrombotic markers can be combined with other clinical parameters (such as prothrombin time and activated partial thromboplastin time) to enhance the diagnostic accuracy of hypercoagulability in pregnant women by comprehensive evaluation. The gene discussed is F2; the disease is thrombophilia.